Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression

Interactions between cancer cells and microenvironment are emerging issue in tumor progression. Aldehyde dehydrogenase 1 (ALDH1) is a recognized cancer stem cell marker but little is known about its role in intratumoral stroma. Therefore, we focused on ALDH1 expression in tumor-associated stroma of breast carcinomas (BrCa). Stromal and tumoral ALDH1 expression was evaluated immunohistochemically in BrCa and their lymph node metastases (LNMs), and related to clinico-pathological characteristics, patients’ outcome, presence of CD68, HLADR, retinoic acid (RA) in stroma, and selected proteins in tumor cells. ALDH1(+) stromal cells were detected in 53% of 374 BrCa and 61% of 102 LNMs. ALDH1(+) stroma in primary tumor correlated to longer disease-free (p = 0.030), metastasis-free (p = 0.024), and overall survival (p = 0.043) having an independent prognostic impact on DFS (multivariate analysis, p = 0.047). It was associated with concomitant presence of HLA-DR(+) stromal cells and RA in tumor cells (both p < 0.001), and inversely associated with vimentin expression in tumor cells (p = 0.036). ALDH1(+) stroma in LNMs correlated inversely to presence of disseminated tumor cells in patients’ bone marrow (p = 0.014) and was independent prognosticator of shorter DFS and MFS (multivariate analysis, p = 0.004 and p = 0.002, respectively). In conclusion, ALDH1 expression in tumor-associated stromal cells indicates reduced BrCa progression, possibly via RA secretion.

[1]  Maria L. Wei,et al.  Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma , 2015, Melanoma research.

[2]  S. Leong,et al.  Micrometastatic cancer cells in lymph nodes, bone marrow, and blood: Clinical significance and biologic implications , 2014, CA: a cancer journal for clinicians.

[3]  Hui Zhang,et al.  Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells. , 2014, Cancer letters.

[4]  S. Pinder,et al.  Aldehyde dehydrogenase and estrogen receptor define a hierarchy of cellular differentiation in the normal human mammary epithelium , 2014, Breast Cancer Research.

[5]  H. Lee,et al.  Colorectal micropapillary carcinomas are associated with poor prognosis and enriched in markers of stem cells , 2013, Modern Pathology.

[6]  Yibin Kang,et al.  The metastasis-promoting roles of tumor-associated immune cells , 2013, Journal of Molecular Medicine.

[7]  W. Biernat,et al.  Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer , 2012, Journal of Translational Medicine.

[8]  Vindhya Koppaka,et al.  Aldehyde Dehydrogenase Inhibitors: a Comprehensive Review of the Pharmacology, Mechanism of Action, Substrate Specificity, and Clinical Application , 2012, Pharmacological Reviews.

[9]  J. Jassem,et al.  Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer , 2012, Pathology & Oncology Research.

[10]  H. Olsson,et al.  Distribution of aldehyde dehydrogenase 1‐positive stem cells in benign mammary tissue from women with and without breast cancer , 2012, Histopathology.

[11]  P. Czapiewski,et al.  CD73 Expression as a Potential Marker of Good Prognosis in Breast Carcinoma , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[12]  J. Mora,et al.  Vitamin A and immune regulation: role of retinoic acid in gut-associated dendritic cell education, immune protection and tolerance. , 2012, Molecular aspects of medicine.

[13]  D. Horst,et al.  The expression pattern of aldehyde dehydrogenase 1 (ALDH1) is an independent prognostic marker for low survival in colorectal tumors. , 2012, Experimental and molecular pathology.

[14]  A. Tangoku,et al.  Aldehyde Dehydrogenase 1 Expression is Associated with Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma , 2012, Annals of Surgical Oncology.

[15]  S. Haywood-Small,et al.  Aldehyde dehydrogenase activity selects for the holoclone phenotype in prostate cancer cells. , 2011, Biochemical and biophysical research communications.

[16]  Douglas B. Evans,et al.  ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma , 2011, PloS one.

[17]  M. Sabel,et al.  EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development , 2011, Modern Pathology.

[18]  A. Tanimoto,et al.  Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node‐positive breast cancers: a long‐term follow‐up study , 2011, Histopathology.

[19]  L. Gudas,et al.  Retinoids, retinoic acid receptors, and cancer. , 2011, Annual review of pathology.

[20]  L. Frati,et al.  Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  V. Assmann,et al.  Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue , 2011, Breast Cancer Research and Treatment.

[22]  M. Koch,et al.  Low expression of aldehyde deyhdrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer , 2011, BMC Cancer.

[23]  A. Allan,et al.  The Role of Human Aldehyde Dehydrogenase in Normal and Cancer Stem Cells , 2011, Stem Cell Reviews and Reports.

[24]  P. V. van Diest,et al.  University of Groningen Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer , 2011 .

[25]  J. Luborsky,et al.  Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors , 2010, Journal of ovarian research.

[26]  H. Yao,et al.  Markers of Tumor-Initiating Cells Predict Chemoresistance in Breast Cancer , 2010, PloS one.

[27]  R. Iacovelli,et al.  Molecular markers in circulating tumour cells from metastatic colorectal cancer patients , 2010, Journal of cellular and molecular medicine.

[28]  S. Schnitt,et al.  Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy , 2010, Modern Pathology.

[29]  Lin Zhang,et al.  Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers , 2010, PloS one.

[30]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[31]  Zhenqiu Liu,et al.  Aldehyde Dehydrogenase 1 A1–Positive Cell Population Is Enriched in Tumor-Initiating Cells and Associated with Progression of Bladder Cancer , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[32]  L. Akslen,et al.  Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer , 2009, British Journal of Cancer.

[33]  Zhenqiu Liu,et al.  ALDH1A1 Is a Marker for Malignant Prostate Stem Cells and Predictor of Prostate Cancer Patients’ Outcome , 2009, Laboratory Investigation.

[34]  義岡 孝子.  Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers : a long-term follow-up study , 2010 .

[35]  J. Reis-Filho,et al.  Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment , 2010, Breast Cancer Research and Treatment.

[36]  Lunxu Liu,et al.  The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time , 2010, BMC Cancer.

[37]  F. Bertucci,et al.  Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer , 2009, Clinical Cancer Research.

[38]  F. Bertucci,et al.  Retinoid signaling regulates breast cancer stem cell differentiation , 2009, Cell cycle.

[39]  Tanja Fehm,et al.  Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients , 2009, Breast Cancer Research.

[40]  T. Taguchi,et al.  Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers , 2009, Clinical Cancer Research.

[41]  Feng Jiang,et al.  Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer , 2009, Molecular Cancer Research.

[42]  R. Beaulieu,et al.  ALDH1 as a functional marker of cancer stem and progenitor cells. , 2009, Stem cells and development.

[43]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[44]  W. Sauerbrei,et al.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2006, Breast Cancer Research and Treatment.

[45]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[46]  W. Sauerbrei,et al.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.

[47]  Vasilis Vasiliou,et al.  Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family , 2005, Human Genomics.

[48]  P. Reczek,et al.  Lung retinol storing cells synthesize and secrete retinoic acid, an inducer of alveolus formation. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[49]  A. Lassar,et al.  Erythropoietin and retinoic acid, secreted from the epicardium, are required for cardiac myocyte proliferation. , 2003, Developmental biology.

[50]  J. Izbicki,et al.  Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. , 1994, Journal of hematotherapy.

[51]  R. Warnke,et al.  Human dendritic cells and macrophages. In situ immunophenotypic definition of subsets that exhibit specific morphologic and microenvironmental characteristics. , 1985, The American journal of pathology.